China Resources Sanjiu Medical & Pharmaceutical Co Ltd

The company maintains a conservative capital structure, with a debt-to-equity ratio of 0.3, indicating limited leverage. Free cash flow of 2.996 billion CNY supports operational flexibility, though net cash is negative after subtracting total debt, signaling potential liquidity constraints. A current ratio of 1.83 suggests adequate short-term liquidity to cover obligations. Profitability metrics show a return on equity of 15.43% and a return on assets of 5.82%, both above the typical thresholds for the pharmaceutical industry, indicating strong capital efficiency and earnings generation. Operating income of 4.852 billion CNY and a gross profit of 17.055 billion CNY reflect a healthy margin structure, though the net income of 3.421 billion CNY suggests some pressure from operating expenses. The company’s revenue is concentrated in its core pharmaceutical segment, with no disclosed geographic breakdown. However, as a Chinese-based firm, it is likely exposed to domestic market dynamics, including regulatory shifts and pricing pressures from the National Healthcare Security Administration. Outlook data is not provided in the current dataset, but historical revenue of 31.603 billion CNY indicates a stable base. Analysts have assigned a mean price target of 37.27 CNY, with a median of 36.00 CNY, and a mean recommendation of 2.09 (leaning toward buy). Risk factors include medium liquidity risk due to negative net cash after debt and a potential for capital structure adjustments. Dilution risk is assessed as low, with no near-term pressure from share issuance or convertible debt. Recent filings and transcripts are not included in the current dataset, but the company’s capital expenditure of -1.271 billion CNY suggests a focus on cost optimization rather than expansion.